Study Demonstrates Promise for Olaparib in Metastatic Castration-Resistant Prostate Cancer

Olaparib was found to be associated with longer progression-free survival and improved measures of response and patient-reported end points than either enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news